DMRA Damora Therapeutics, Inc.

P/E --
Forward P/E --
Price/Sales --
Beta 1.509
Div Yield --
Market Cap --

Company Analysis

Latest News

πŸ”΄ Damora Therapeutics is trading 5% down today as Treasury yields climb

Damora Therapeutics is trading 5.12% down now at $30.78, with broader risk-off conditions the most likely explanation as Treasury yields resumed climbing and...

Damora Therapeutics Lost More Money Than Expected Building Its Blood-Cancer Bet β€” Can $540 Million in Cash Buy Enough Time?

Damora Therapeutics Lost More Money Than Expected Building Its Blood-Cancer Bet β€” Can $540 Million in Cash Buy Enough Time?

Shares of Damora Therapeutics (DMRA) cratered 8.6% to $27.00 in pre-market trading after the clinical-stage biotech reported second-quarter results that left...

πŸ”΄ Damora Therapeutics is trading 8.6% down in pre-market after quarterly net loss widened to $31.2 million

Damora Therapeutics is trading at $27.00 (-8.6%) after second-quarter results reported on August 10, 2026. β€’ Q2 EPS of -$0.39 beat the -$0.43 consensus...

Damora Therapeutics, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026

Damora Therapeutics is expected to report zero revenue and a consensus EPS of -$0.38 for Q2 2026, with the current share price of $29.92 sitting significantly...

Damora Therapeutics, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026

Damora Therapeutics is expected to report zero revenue and a consensus EPS loss of $0.38 for Q2 2026, with the stock currently trading at $29.50 compared to a...

🟒 Damora Therapeutics is trading 5.4% up today amid broader market risk-on sentiment

Damora Therapeutics is trading 5.4% higher at $29.86 as a broader market rebound lifts equities despite a lack of company-specific catalysts. β€’ The upward...

Damora Therapeutics Earns Buy Rating, Jefferies Sees 73% Upside in Blood Cancer

Damora Therapeutics Earns Buy Rating, Jefferies Sees 73% Upside in Blood Cancer

Jefferies initiated coverage of Damora Therapeutics (DMRA) on July 27, 2026. Analyst Akash Tewari issued a Buy rating for the stock. The firm set a price...

🟒 Damora Therapeutics is trading 5.1% up today amid risk-on sentiment

Damora Therapeutics is trading 5.1% up at $30.30 today amid a broader market risk-on sentiment, as there are no clear company-specific catalysts for the...

Damora Therapeutics Slumps, Facing Incyte’s Faster and Easier Rival Drug

Damora Therapeutics Slumps, Facing Incyte’s Faster and Easier Rival Drug

Damora Therapeutics (DMRA) shares declined on July 22, 2026. Reports indicate a competing blood disorder drug from Incyte will likely reach the market one...

🟒 Damora Therapeutics is trading 5.3% up today after HC Wainwright reiterates Buy rating and $45 price target

Damora Therapeutics is trading 5.3% higher at $34.74 after HC Wainwright reiterated its Buy rating and $45 price target, highlighting significant upside...

🟒 Damora Therapeutics is trading 10.2% up

Damora Therapeutics is trading at $34.68, up 10.2% from a comparison close of $31.48 during regular trading. This is a price-action follow-up, so a separate...

🟒 Damora Therapeutics is trading 5.75% up today on pipeline milestones and strong cash runway

Damora Therapeutics is trading 5.75% up at $33.29 as traders refocus on the company's near-term blood-disorder pipeline milestones and strong cash runway. β€’...

🟒 Damora Therapeutics is trading 10.1% up

Damora Therapeutics is trading at $30.84, up 10.1% from a comparison close of $28.00 during regular trading. This is a price-action follow-up, so a separate...

🟒 Damora Therapeutics is trading 5.3% up today, rebounding on improved risk sentiment

Damora Therapeutics is trading 5.3% up at $29.49, reversing last week’s pullback amid improving risk sentiment following softer June CPI inflation. β€’ The move...

πŸ”΄ Damora Therapeutics is trading 5.1% down today on profit-taking after a recent rally

Damora Therapeutics is trading 5.1% down today at $27.08 on profit-taking and price normalization following a volatile two-week rally. β€’ The reversal comes...

πŸ”΄ Damora Therapeutics is trading 5.4% down today after reversing gains from its recent rally

Damora Therapeutics is trading at $29.11 (-5.43%) in a sharp move lower that appears to be a price-action reversal following a 10.8% rise in the prior...

🟒 Damora Therapeutics is trading 10.8% up

Damora Therapeutics is trading at $30.50, up 10.8% from a comparison close of $27.53 during regular trading. This is a price-action follow-up, so a separate...

Damora Therapeutics Jumps 7.6% on Pipeline Hopes, but Can Investor Enthusiasm Survive Without Hard News?

Damora Therapeutics Jumps 7.6% on Pipeline Hopes, but Can Investor Enthusiasm Survive Without Hard News?

Shares of Damora Therapeutics surged 7.6% to $29.62 on July 9, reclaiming nearly all of the prior session's 8.23% selloff β€” despite no new company...

🟒 Damora Therapeutics is trading 7.6% up today on investor positioning ahead of pipeline milestones

Damora Therapeutics is trading 7.6% up at $29.62 on investor positioning ahead of pipeline milestones, rebounding from the previous session's 8.23% decline. β€’...

πŸ”΄ DMRA extends move to 7.4% down

DMRA is trading at $27.77, down 7.4% versus the comparison close of $30.00 during regular trading. This is a price-movement alert; no separate company-specific...